	Dead, N = 980			Alive, N = 1,748		
Characteristics	VAP N = 511	Hospital- acquired BSI N = 364	Healthcare- associated BSI N = 105	VAP N = 579	Hospital- acquired BSI N = 764	Healthcare- associated BSI N = 405
Age (years)		- 6 00		10 01	46 06	
Mean ± SD	57 ± 22	56 ± 22	53 ± 25	49 ± 24	46 ± 26	52 ± 27
Sex	160 (220/)	166 (460/)	47 (450/)	104 (220/)	220 (440/)	107 (400/)
Female Male	168 (33%)	166 (46%)	47 (45%)	184 (32%)	338 (44%)	197 (49%)
Region	343 (67%)	198 (54%)	58 (55%)	395 (68%)	426 (56%)	208 (51%)
Eastern Mediterranean Region	38 (7.4%)	19 (5.2%)	16 (15%)	47 (8.1%)	42 (5.5%)	29 (7.2%)
South-East Asian Region	276 (54%)	204 (56%)	54 (51%)	182 (31%)	340 (45%)	196 (48%)
Western Pacific Region	197 (39%)	141 (39%)	35 (33%)	350 (60%)	382 (50%)	180 (44%)
World Bank income status	137 (3370)	141 (5570)	33 (3370)	330 (0070)	302 (3070)	100 (4470)
High income	18 (3.5%)	25 (6.9%)	13 (12%)	50 (8.6%)	115 (15%)	90 (22%)
Upper middle income	347 (68%)	242 (66%)	38 (36%)	357 (62%)	442 (58%)	188 (46%)
Lower middle income	114 (22%)	82 (23%)	38 (36%)	150 (26%)	147 (19%)	78 (19%)
Low income	32 (6.3%)	15 (4.1%)	16 (15%)	22 (3.8%)	60 (7.9%)	49 (12%)
Primary admission reason	, ,	,	` /	,	,	,
Cardiovascular condition	36 (7.0%)	25 (6.9%)	4 (3.8%)	25 (4.3%)	44 (5.8%)	9 (2.2%)
Connective tissue disease	4 (0.8%)	0 (0%)	0 (0%)	1 (0.2%)	9 (1.2%)	0 (0%)
Dermatological disease	0 (0%)	6 (1.6%)	0 (0%)	2 (0.3%)	9 (1.2%)	2 (0.5%)
Endocrine / Metabolic disorder	7 (1.4%)	7 (1.9%)	2 (1.9%)	6 (1.0%)	14 (1.8%)	1 (0.2%)
Gastrointestinal disorder	40 (7.8%)	38 (10%)	15 (14%)	28 (4.8%)	88 (12%)	71 (18%)
Genitourinary disorder	1 (0.2%)	3 (0.8%)	2 (1.9%)	1 (0.2%)	5 (0.7%)	5 (1.2%)
Gynaecological disorder	0 (0%)	1 (0.3%)	0 (0%)	2 (0.3%)	11 (1.4%)	4 (1.0%)
Haematological disease	6 (1.2%)	9 (2.5%)	2 (1.9%)	3 (0.5%)	39 (5.1%)	6 (1.5%)
Infectious disease	90 (18%)	51 (14%)	21 (20%)	82 (14%)	88 (12%)	127 (31%)
Neurological disease	60 (12%)	27 (7.4%)	4 (3.8%)	124 (21%)	70 (9.2%)	13 (3.2%)
Oncologic disorder	11 (2.2%)	46 (13%)	11 (10%)	17 (2.9%)	123 (16%)	59 (15%)
Orthopaedic condition	7 (1.4%)	8 (2.2%)	0 (0%)	8 (1.4%)	15 (2.0%)	4 (1.0%)
Pulmonary disease	144 (28%)	53 (15%)	15 (14%)	131 (23%)	63 (8.2%)	30 (7.4%)
Renal disorder	11 (2.2%)	24 (6.6%)	9 (8.6%)	15 (2.6%)	35 (4.6%)	29 (7.2%)
Trauma	34 (6.7%)	12 (3.3%)	4 (3.8%)	79 (14%)	36 (4.7%)	2 (0.5%)
Undetermined	5 (1.0%)	3 (0.8%)	1 (1.0%)	1 (0.2%)	1 (0.1%)	2 (0.5%)
Others	55 (11%)	51 (14%)	15 (14%)	54 (9.3%)	114 (15%)	41 (10%)
Charlson comorbidity index						
Median [IQR]	0 [0, 1]	1 [0, 2]	1 [0, 2]	0 [0, 1]	0 [0, 2]	1 [0, 2]
Severity score of disease*						
Median [IQR]	8 [8, 12]	8 [4, 9]	8 [4, 8]	8 [4, 8]	4 [0, 8]	4 [0, 8]
Usage of medical devices $^{^{\dagger}}$						
Yes	510 (100%)	362 (99%)	100 (95%)	578 (100%)	744 (97%)	385 (95%)
No	1 (0.2%)	2 (0.5%)	5 (4.8%)	1 (0.2%)	20 (2.6%)	20 (4.9%)
ICU/HD admissions of enrolment	()	()	- ()	()	(,	(,
Yes	426 (83%)	263 (72%)	68 (65%)	537 (93%)	396 (52%)	118 (29%)
No	85 (17%)	101 (28%)	37 (35%)	42 (7.3%)	368 (48%)	287 (71%)
Length of ICU stay (days) [#]	` ,	` ,	` ,	, ,	` ,	` ,
Median [IQR]	6 [1, 12]	3 [0, 10]	1 [0, 6]	10 [2, 23]	0 [0, 7]	0 [0, 0]
Duration of mechanical ventilation (days) [#]	6 [2, 12]	1 [0 7]	0.10 2.1	C [O 10]	0.00	0.00
Median [IQR]	6 [2, 12]	1 [0, 7]	0 [0, 2]	6 [0, 18]	0 [0, 0]	0 [0, 0]
Types of pathogens	270 (740/)	200 (020/)	07 (020/)	424 (720/)	600 (000/)	272 (020/)
Monomicrobial	379 (74%)	298 (82%)	97 (92%)	424 (73%)	680 (89%)	372 (92%)
Polymicrobial Gram-negative bacteria	132 (26%)	66 (18%)	8 (7.6%)	155 (27%)	84 (11%)	33 (8.1%)
Third-generation cephalosporins-susceptible	83 (16%)	79 (22%)	50 (48%)	165 (28%)	314 (41%)	198 (49%)
Third-generation cephalosporms-susceptible Third-generation cephalosporins-resistant	59 (12%)	85 (23%)	35 (33%)	95 (16%)	214 (28%)	147 (36%)
Carbapenem-resistant	369 (72%)	200 (55%)	20 (19%)	319 (55%)	236 (31%)	60 (15%)
	· · · · · · · · · · · · · · · · · · ·		· · · · ·	· · · · · · · · · · · · · · · · · · ·	` ′	00 (10/0)
* Standardized severity score included qSOFA for adults,			-			-
Medical devices involved one or more of the following: peripheral intravenous catheter, central venous catheter, indwelling urinary catheter, and intubation/machine ventilator.						

Follow-up 28 days since the index infection.